الصفحة الرئيسية>>Signaling Pathways>> Membrane Transporter/Ion Channel>> P-glycoprotein>>NSC 23925

NSC 23925

رقم الكتالوجGC18470

NSC 23925 هو مثبط جديد وانتقائي وفعال للبروتين P-glycoprotein (Pgp).

Products are for research use only. Not for human use. We do not sell to patients.

NSC 23925 التركيب الكيميائي

Cas No.: 858474-14-3

الحجم السعر المخزون الكميّة
1mg
37٫00
متوفر
5mg
112٫00
متوفر
10mg
194٫00
متوفر
25mg
428٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description of NSC 23925

NSC23925 is a novel, selective and effective P-glycoprotein (Pgp) inhibitor.

NSC23925 is a novel, selective and effective P-glycoprotein (Pgp) inhibitor. SKOV-3 cells with long-term exposure of 1 μM NSC23925 show stable growth in culture medium. NSC23925 specifically inhibits Pgp overexpression to prevent the emergence of paclitaxel resistance during paclitaxel treatment[1]. NSC23925 reverses chemoresistance in a wide variety of tumor types where Multidrug resistance 1 (MDR1) is highly expressed. Maximal reversal of MDR is typically seen in NSC23925 doses between 0.5 and 1 µM. The IC50 for NSC23925 is 8 µM in SKOV-3/SKOV-3TR and 25 µM in OVCAR8/OVCAR8TR cell lines, whereas the mean concentration of NSC23925 required for maximal reversal of resistance in SKOV-3TR or OVCAR8TR to cytotoxic drugs is 0.5 µM to 1 µM[2].

Both saline alone and NSC23925 alone treated tumors grow progressively. The usage of NSC23925 in paclitaxel chemotherapy significantly prolongs anticancer efficacy of paclitaxel[1].

References:
[1]. Yang X, et al. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. Int J Cancer. 2015 Oct 15;137(8):2029-39.
[2]. Duan Z, et al. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One. 2009 Oct 12;4(10):e7415.

Protocol of NSC 23925

Cell experiment:

To determine whether NSC23925 can prevent the emergence of paclitaxel resistance, paclitaxel resistant ovarian cancer cells are used. In brief, 1×105 SKOV-3 cells are suspended in culture media containing paclitaxel alone, 1 μM NSC23925 alone, or paclitaxel in combination with 1 μM NSC23925. When the cells are cultured to 90% confluence, 1×105 cells are reseeded in a new tissue culture flask, and the paclitaxel dose is increased stepwise. The initial concentration of paclitaxel is 0.0001 μM. At different selection points cell sublines are collected and stored at liquid nitrogen for further analysis[1].

Animal experiment:

Nude female mice at approximately 3 to 4 weeks of age are used. To evaluate the effects of NSC23925 on the induction of paclitaxel resistance in vivo, the paclitaxel resistant cells are established in human ovarian cancer xenograft models. Briefly, on day 1, approximately 2×106 parental sensitive SKOV-3 cells are injected subcutaneously with Matrigel into the flanks of 3 to 4-week-old female nude mice. Administration is initiated 12 days after injection of tumor cells. The mice are randomized into 4 groups and treated intraperitoneally with either saline alone, NSC23925 alone (50 mg/kg), paclitaxel (25 mg/kg) alone, or paclitaxel (25 mg/kg) in combination with NSC23925 (50 mg/kg) twice per week for 3 weeks followed by a treatment-free interval of 2 weeks. The second round of treatment is then continued. The size of tumors is recorded twice a week beginning on day 13. Tumor volume is measured with a digital caliper and calculated according to the formula (length×width2)/2[1].

References:

[1]. Yang X, et al. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. Int J Cancer. 2015 Oct 15;137(8):2029-39.
[2]. Duan Z, et al. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One. 2009 Oct 12;4(10):e7415.

Chemical Properties of NSC 23925

Cas No. 858474-14-3 SDF
Chemical Name 2-(4-methoxyphenyl)-α-2-piperidinyl-4-quinolinemethanol, dihydrochloride
Canonical SMILES OC(C1NCCCC1)C2=CC(C3=CC=C(OC)C=C3)=NC4=C2C=CC=C4.Cl.Cl
Formula C22H24N2O2.2HCl M.Wt 421.4
الذوبان Soluble in DMSO Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of NSC 23925

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.373 mL 11.8652 mL 23.7304 mL
5 mM 0.4746 mL 2.373 mL 4.7461 mL
10 mM 0.2373 mL 1.1865 mL 2.373 mL
  • حاسبة المولارية

  • حاسبة التخفيف

  • Molecular Weight Calculator

كتلة
=
تركيز
x
مقدار
x
ميغاواط *
 
 
 
** عند إعداد حلول المخزون، دائمًا استخدم الوزن الجزيئي الخاص بالدفعة للمنتج على ملصق القارورة MSDS / CoA (متوفر عبر الإنترنت).

احسب

In vivo Formulation Calculator (Clear solution) of NSC 23925

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

مراجعات

Review for NSC 23925

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NSC 23925

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.